Shandong Xinhua Pharmaceutical Company Limited Class A
0.67
EUR
+0.01
(+1.53%)
ISIN
CNE100000411
Return %
Stock
S&P 500
1Y
-25.28
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Wen Hui Xu
- Full Time Employees
- 7,240
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- No. 1 Lutai Avenue Zibo SD China 255086
- IPO Date
- Dec 31, 1996
- Website
- xhzy.com
- Similar Companies
- Business
- Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) develops, manufactures, and sells bulk pharmaceuticals, preparations, pharmaceutical intermediates, and chemical products primarily in China, the Americas, Europe, and other international markets. Founded in 1943 and headquartered in Zibo, Shandong Province, People's Republic of China, the company offers a broad portfolio of products under the Xinhua brand, including antipyretic and analgesic drugs such as metamizole sodium, caffeine, aminopyrine, aspirin, and ibuprofen; cardiovascular and cerebrovascular drugs; anti-infective drugs like pipemidic acid; central nervous system drugs such as L-dopa; steroidal hormone drugs like hydrocortisone; prepared Chinese herbal medicines for decoction; traditional Chinese medicines; antibiotics; biochemical medicines; anesthetics; anti-psychotic drugs; protein assimilation preparations; and peptide hormones. It also provides contract manufacturing services for active pharmaceutical ingredients (APIs), intermediates, OTC products, and generics; veterinary drugs and fodders; raw materials and intermediates; internet data, sales, and information services for pharmaceuticals and medical devices; steroid system APIs and intermediates; chemical raw materials; and engages in property management, nonresidential real estate leasing, electrical equipment engineering, and chemical equipment installation. The company maintains five manufacturing sites covering over 3 million square meters, advanced GMP-certified facilities, and certifications including ISO9001, ISO14001, ISO10012, COS, FDA approvals, HALAL, and KOSHER, positioning it as China's largest producer and exporter of antipyretic analgesics and a key domestic supplier of cardio-cerebrovascular, anti-infective, neurological, and steroidal hormone drugs. Shandong Xinhua has established long-term strategic partnerships with over 200 multinational companies, including Roche, Bayer, and Merck, and more recently with over 15 international pharmaceutical firms contributing to 30% of revenue through collaborative projects as of 2023. In 2025, it received China's supplementary approval for Epinephrine Hydrochloride Injection and marketing approval notification for Prednisolone Acetate, alongside ongoing clinical trials for drugs like Irisquinone targeting head and neck neoplasms, reflecting expansions in finished dosage forms and regulatory achievements. As a dual-listed A-share and H-share entity and a subsidiary in the pharmaceutical sector of Shandong Hualu Holdings Co., Ltd., the company continues to invest heavily in R&D, allocating approximately ¥800 million in 2023 to high-end innovations while exporting to global markets and pursuing overseas branches.